Antibody Molecules to C5AR1 and Uses Thereof
AssigneeVisterra, Inc.
InventorsKarthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
Life of this patent
Estimating the term…
Abstract
Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
Claims36
1-2. (canceled)
An antibody molecule capable of binding to complement component 5a receptor 1 (C5aR1), wherein the antibody molecule competes with a C5aR1 antibody molecule comprising:
- an HCDR1 comprising an amino acid sequence of SEQ ID NO:
- 656, an HCDR2 comprising an amino acid sequence of SEQ ID NO:
- 776, and an HCDR3 comprising and amino acid sequence of SEQ ID NO:
- 896, an LCDR1 comprising an amino acid sequence of SEQ ID NO:
- 715, an LCDR2 comprising an amino acid sequence of SEQ ID NO:
- 835, and an LCDR3 comprising an amino acid sequence of SEQ ID NO:
- 955.
The antibody molecule of claim 1, wherein the antibody molecule binds to an epitope on Site I of C5aR1, wherein the epitope on Site I comprises amino acid residues of SEQ ID NO:
- 1449 or SEQ ID NO:
- 1452.
5-8. (canceled)
The antibody molecule of claim 1, comprising a VH and/or a VL, wherein the VH comprises:
- i. an HCDR1 comprising an amino acid sequence of SEQ ID NO:
- 656;
- ii. an HCDR2 comprising an amino acid sequence of SEQ ID NO:
- 776;
- and
- iii. an HCDR3 comprising an amino acid sequence of SEQ ID NO:
- 896;
- and
- wherein the VL comprises:
- i. an LCDR1 comprising an amino acid sequence of SEQ ID NO:
- 715,
- ii. an LCDR2 comprising an amino acid sequence of SEQ ID NO:
- 835, and
- iii. an LCDR3 comprising an amino acid sequence of SEQ ID NO:
- 955.
10-12. (canceled)
The antibody molecule of claim 1, comprising a VH and/or a VL,
- wherein the VH comprises:
- i. an HCDR1 comprising an amino acid sequence of SEQ ID NO:
- 603;
- ii. an HCDR2 comprising an amino acid sequence of SEQ ID NO:
- 723;
- and
- iii. an HCDR3 comprising an amino acid sequence of SEQ ID NO:
- 843;
- and
- wherein the VL comprises:
- i. an LCDR1 comprising an amino acid sequence of SEQ ID NO:
- 663,
- ii. an LCDR2 comprising an amino acid sequence of SEQ ID NO:
- 783, and
- iii. an LCDR3 comprising an amino acid sequence of SEQ ID NO:
- 903.
(canceled)
The antibody molecule of claim 1, comprising a VH and/or a VL,
- wherein the VH comprises:
- i. an HCDR1 comprising an amino acid sequence of SEQ ID NO:
- 611;
- ii. an HCDR2 comprising an amino acid sequence of SEQ ID NO:
- 731;
- and
- iii. an HCDR3 comprising an amino acid sequence of SEQ ID NO:
- 851;
- and
- wherein the VL comprises:
- i. an LCDR1 comprising an amino acid sequence of SEQ ID NO:
- 671,
- ii. an LCDR2 comprising an amino acid sequence of SEQ ID NO:
- 792, and
- iii. an LCDR3 comprising an amino acid sequence of SEQ ID NO:
- 911.
(canceled)
An antibody molecule capable of binding to complement component 5a receptor 1 (C5aR1), wherein the antibody molecule competes with a C5aR1 antibody molecule comprising:
- an HCDR1 comprising an amino acid sequence of SEQ ID NO:
- 612, an HCDR2 comprising an amino acid sequence of SEQ ID NO:
- 732, and an HCDR3 comprising and amino acid sequence of SEQ ID NO:
- 852, an LCDR1 comprising an amino acid sequence of SEQ ID NO:
- 672, an LCDR2 comprising an amino acid sequence of SEQ ID NO:
- 792, and an LCDR3 comprising an amino acid sequence of SEQ ID NO:
- 912.
19-22. (canceled)
24-27. (canceled)
(canceled)
31-37. (canceled)
A multispecific antibody molecule capable of binding to complement component 5a receptor 1 (C5aR1), wherein the antibody molecule comprises:
- a first immunoglobulin variable region that binds to a first epitope, and a second immunoglobulin variable region that binds to a second epitope,
- wherein the first epitope is on Site II of C5aR1, comprising amino acid residues of SEQ ID NO:
- 1450;
- and
- wherein the second epitope is on Site I of C5aR1 comprising an amino acid residues of SEQ ID NO:
- 1449 or SEQ ID NO:
- 1452.
39-40. (canceled)
43-50. (canceled)
A pharmaceutical composition comprising the antibody molecule of claim 1, optionally further comprising a pharmaceutically acceptable carrier or excipient.
A combination comprising the antibody molecule of claim 1, and a second therapeutic agent.
53-56. (canceled)
A nucleic acid molecule comprising a nucleotide sequence encoding the antibody molecule of claim 1.
(canceled)
(canceled)
A method of treating a disease or disorder, the method comprising administering to a subject in need thereof an effective amount of the antibody molecule of claim 1, thereby treating the disorder.
63-69. (canceled)
A method of modulating (e.g., decreasing) a C5aR1 activity, the method comprising contacting a cell or a subject in need thereof an effective amount of the antibody molecule of claim 1, thereby modulating (e.g., decreasing) the C5aR1 activity.
(canceled)
Dependencies are inferred from the claim text.